GLPwatch
Papers (9189)
Page 24 of 154, ranked by citation count.
- Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery.
- A Long-Acting PYY<sub>3-36</sub> Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates.
- Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
- Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.
- Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R.
- The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
- Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.
- A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
- Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
- Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
- Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.
- Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
- Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.
- Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.
- Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
- Impact of system delay on infarct size, myocardial salvage index, and left ventricular function in patients with ST-segment elevation myocardial infarction.
- Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.
- Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial.
- Progress in Pharmacotherapy for Obesity.
- Exendin-4 and Liraglutide Attenuate Glucose Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent Autophagy.
- Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
- Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.
- Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.
- Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version.
- Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
- Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
- A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
- Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
- Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.
- Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells.
- Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system.
- Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes.
- Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
- Phytotherapy in diabetes: Review on potential mechanistic perspectives.
- The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study.
- Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
- Exenatide therapy in insulin-treated type 2 diabetes and obesity.
- Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis.
- Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.
- Regulation of microRNA-375 by cAMP in pancreatic β-cells.
- Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model.
- Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.
- Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
- Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels.
- Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.
- GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.
- Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss.
- Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
- Phasic dopamine responses to a food-predictive cue are suppressed by the glucagon-like peptide-1 receptor agonist Exendin-4.
- Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
- The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway.
- Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.
- Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.
- Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.
- Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway.
- Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist.
- Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.